First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after ...

BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...

Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.

Labcorp , a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians ...

The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) compared to docetaxel in patients with TROP2 NMR positive locally advanced or ...

Experts discuss the critical unmet needs in HER2-mutant non-small cell lung cancer, highlighting disparities in testing and ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...

Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for expediting diagnoses and guiding patient treatment.

The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.